- Label includes full spectrum of PKU patients - - European launch preparations underway - WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the marketing authorization application for Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The opinion includes a broad label inclusi ...

PTC Therapeutics (PTCT) Update / Briefing July 19, 2023 12:00 PM ET Speaker0 Thank you for standing by, and welcome to the PTC Therapeutics PKU Deep Dive. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Kylie O'Keefe, chief commerc ...

PTC Therapeutics (PTCT) Update / Briefing May 17, 2023 08:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. Welcome to the Affinity Topline Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I will now hand the conference over to your speaker host, Doctor. Matthew Klein. Please go ahead. Speaker1 Thank you all for joining ...